Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-9966
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment ; volume:36 ; number:1 ; day:18 ; month:4 ; year:2017 ; pages:1-17 ; date:12.2017
Journal of experimental & clinical cancer research ; 36, Heft 1 (18.4.2017), 1-17, 12.2017

Schlagwort
Biopharmazie
Pharmakodynamik
Pharmakokinetik

Urheber
Jaruskova, Monika
Beteiligte Personen und Organisationen
Curik, Nikola
Hercog, Rajna
Polivkova, Vaclava
Motlova, Eliska
Beneš, Vladimír
Klamová, Hana
Pecherkova, Pavla
Belohlavkova, Petra
Vrbacky, Filip
Machova Polakova, Katerina
SpringerLink (Online service)

DOI
10.1186/s13046-017-0523-3
URN
urn:nbn:de:1111-201705032529
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Jaruskova, Monika
  • Curik, Nikola
  • Hercog, Rajna
  • Polivkova, Vaclava
  • Motlova, Eliska
  • Beneš, Vladimír
  • Klamová, Hana
  • Pecherkova, Pavla
  • Belohlavkova, Petra
  • Vrbacky, Filip
  • Machova Polakova, Katerina
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Imatinib Mesylate in Chronic Myeloid Leukemia

Imatinib Mesylate in Chronic Myeloid Leukemia

Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia

Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia

Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia

Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia

Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients

Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia

Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

Multiple Small Bowel Perforations in a Patient of Chronic Myeloid Leukemia on Imatinib

Multiple Small Bowel Perforations in a Patient of Chronic Myeloid Leukemia on Imatinib

Profile of Pediatric Chronic Myeloid Leukemia in the Era of Imatinib: A Study from South India

Profile of Pediatric Chronic Myeloid Leukemia in the Era of Imatinib: A Study from South India

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

Verbundene Objekte